Panmure Liberum acted as Nominated Adviser, Joint Bookrunner and Joint Broker on Scancell Holdings plc’s upsized £11.3 million fundraise

Scancell is a clinical stage immunotherapy company that is leveraging its proprietary research, built up over many years of studying the human adaptive immune system, to generate novel medicines to treat significant unmet needs in cancer. The net use of proceeds of the fundraise is expected to allow the company to further progress its lead cancer vaccine SCIB1 and the next generation iSCIB1+ to treat advanced melanoma, whilst also extending the group's cash runway to the second half of 2026.